TrialSignal
Clinical trial intelligence report
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT05140811
Status
UNKNOWN
Phase
PHASE1
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Executive brief
Investment-Ready Snapshot
Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS is a PHASE1 clinical asset sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in Acute Myeloid Leukemia, Myelodysplastic Syndromes. SEO and diligence focus: IMM01, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05140811
Indication
Acute Myeloid Leukemia
Modality
small molecule
Target
IMM01, Azacitidine
Intervention
IMM01, Azacitidine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.